Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions

被引:101
作者
Hendriks, R. J. [1 ]
van Oort, I. M. [1 ]
Schalken, J. A. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Postbus 9101, NL-6500 HB Nijmegen, Netherlands
关键词
HEALTH INDEX PHI; ANTIGEN; 3; PCA3; ACTIVE SURVEILLANCE; FUSION TRANSCRIPTS; UNNECESSARY BIOPSY; GENE FUSION; DIAGNOSIS; IMPROVE; MEN; SERUM;
D O I
10.1038/pcan.2016.59
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making. These include Prostate Health Index (PHI), prostate cancer antigen 3 (PCA3), four-kallikrein panel (4K), transmembrane protease serine 2-ERG (TMPRSS2-ERG), ExoDx Prostate Intelliscore, SelectMDx and the Mi-Prostate score. Only few head-to-head studies are available for these new fluid-based biomarkers and/or models. The blood-based PHI and urinary PCA3 are two US Food and Drug Administration-approved biomarkers for diagnosis of PCa. In the second part of this review, we give an overview of published studies comparing these two available biomarkers for prediction of (1) PCa upon prostate biopsy, (2) pathological features in radical prostatectomy specimen and (3) significant PCa in patients eligible for active surveillance. RESULTS: Studies show opposing results in comparison of PHI with PCA3 for prediction of PCa upon initial and repeat prostate biopsy. PHI and PCA3 are able to predict pathological findings on radical prostatectomy specimen, such as tumor volume and Gleason score. Only PHI could predict seminal vesicle invasion and only PCA3 could predict multifocality. There is some evidence that PHI outperforms PCA3 in predicting significant PCa in an active surveillance population. CONCLUSIONS: Future research should focus on independent validation of promising fluid-based biomarkers/models, and prospective comparison of biomarkers with each other.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 50 条
  • [1] Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers
    Jin, Wei
    Fei, Xiang
    Wang, Xia
    Song, Yan
    Chen, Fangjie
    MEDIATORS OF INFLAMMATION, 2020, 2020
  • [2] Urinary biomarkers for prostate cancer
    Wei, John T.
    CURRENT OPINION IN UROLOGY, 2015, 25 (01) : 77 - 82
  • [3] Clinical use of novel urine and blood based prostate cancer biomarkers: A review
    Dijkstra, S.
    Mulders, P. F. A.
    Schalken, J. A.
    CLINICAL BIOCHEMISTRY, 2014, 47 (10-11) : 889 - 896
  • [4] Urinary biomarkers for prostate cancer: a review
    Hessels, Daphne
    Schalken, Jack A.
    ASIAN JOURNAL OF ANDROLOGY, 2013, 15 (03) : 333 - 339
  • [5] The future of blood-based biomarkers for the early detection of breast cancer
    Loke, Sau Yeen
    Lee, Ann Siew Gek
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : 54 - 68
  • [6] Novel blood-based microRNA biomarkers for diagnosis of pancreatic cancer: a meta-analysis
    Meng, Qing-Cai
    Qiu, Wang-Wang
    Wen, Zi-Qiang
    Wang, Hong-Cheng
    Shan, Ze-Zhi
    Yuan, Zhou
    Huang, Xin-Yu
    TUMORI JOURNAL, 2015, 101 (02): : 199 - 205
  • [7] Serum and urinary biomarkers for detection and active surveillance of prostate cancer
    Becerra, Maria F.
    Bhat, Abhishek
    Mouzannar, Ali
    Atluri, Venkatasai S.
    Punnen, Sanoj
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 593 - 597
  • [8] Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies
    Constancio, Vera
    Barros-Silva, Daniela
    Jeronimo, Carmen
    Henrique, Rui
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (05) : 367 - 375
  • [9] URINARY BIOMARKERS IN THE DIAGNOSIS OF PROSTATE CANCER
    Ballesteros Ruiz, Cristina
    Alvarez-Maestro, Mario
    Aguilera Bazan, Alfredo
    Martinez-Pineiro, Luis
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (02): : 165 - 172
  • [10] Blood-based biomarkers and novel technologies for the diagnosis of colorectal cancer and adenomas: a narrative review
    Magowan, Drew
    Abdulshafea, Mansour
    Thompson, Dominic
    Rajamoorthy, Shri-Ishvarya
    Owen, Rhiannon
    Harris, Dean
    Prosser, Susan
    BIOMARKERS IN MEDICINE, 2024, 18 (09) : 495 - 508